- Home
- SKYA vs MREO Comparison
SKYA vs MREO Comparison
Compare SKYA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYA | MREO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.7M | 50.3M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SKYA | MREO |
|---|---|---|
| Price | $2.79 | $0.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $1.97 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 11-16-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | $204,120.00 | ★ $500,000.00 |
| Revenue This Year | $35,369.33 | N/A |
| Revenue Next Year | $9.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $0.20 |
| 52 Week High | $2.83 | $2.37 |
Technical Indicators
Market Signals| Indicator | SKYA | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 75.68 | 45.78 |
| Support Level | $1.60 | $0.28 |
| Resistance Level | N/A | $0.35 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 98.37 | 13.32 |
Price Performance
Historical ComparisonAbout SKYA SkyAI Inc. Common Stock
SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company's platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).